Eagle’s Eye View: New Guidelines for Treatment of Acute PE
In this week’s View, Dr. Eagle looks at findings from the Evolut Low Risk trial in which self-expanding transcatheter aortic valve replacement (TAVR) versus surgery at six years in low-risk patients with aortic stenosis (AS) is considered. He then explores the TUXEDO-2 Trial evaluating ticagrelor versus prasugrel in percutaneous coronary intervention patients with diabetes and multivessel coronary disease (MVD). Finally, Dr. Eagle examines the first-ever release of the AHA/ACC guideline for treatment and management of acute pulmonary embolism (PE) in adults.
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Anticoagulation Management, Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention, Pulmonary Hypertension and Venous Thromboembolism, Valvular Heart Disease, Vascular Medicine, Atherosclerotic Disease (CAD/PAD), Anticoagulation Management and Venothromboembolism, Aortic Surgery, Cardiac Surgery and VHD, Interventions and Coronary Artery Disease, Interventions and Structural Heart Disease, Interventions and Vascular Medicine, Congenital Heart Disease and Pediatric Cardiology
Keywords: Aortic Valve Stenosis, Stroke, Percutaneous Coronary Intervention, Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus, Thrombolytic Therapy, Embolectomy, Catheters, Thrombosis, Lung Diseases, Emergency Medicine, Thrombectomy, Thrombophilia, Heparin, Low-Molecular-Weight, Pulmonary Embolism, Neoplasms, Anticoagulants, Venous Thromboembolism, Heparin, Pregnancy
